Table 2. Inter-visit difference in group A (montelukast-placebo group).
Phase I | P value | Phase II | P value | |||
---|---|---|---|---|---|---|
Visit 2 (Week 0) | Visit 4 (Week 8) | Visit 5 (Week 10) | Visit 7 (Week 18) | |||
SCORAD index | 44.6±18.3 | 40.7±17.6 | 0.48 | 41.7±19.9 | 34.5±17.4 | 0.21 |
U-LTE4 (pg/mL) | 585.3±428.1 | 542.7±429.5 | 0.74 | 526.7±412.2 | 690.2±385.9 | 0.18 |
U-EDN (ng/mL) | 1,106.7±743.9 | 883.0±742.2 | 0.32 | 1,236.7±749.2 | 1,016.6±573.3 | 0.28 |
SCORAD, SCORing Atopic Dermatitis; U-LTE4, Urine leukotriene E4; U-EDN, Urine eosinophil-derived neurotoxin.